Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Updated KarMMa results: ide-cel in R/R myeloma

Larry Anderson • 4 Jun 2021
ASCO 2021
Multiple Myeloma Idecabtagene vicleucel
KarMMa

Larry D Anderson, MD, PhD, University of Texas Southwestern Medical Center, Dallas, TX, discusses the updated results from KarMMa (NCT03361748), a Phase III study evaluating the use of idecabtagene vicleucel (ide-cel), a BCMA-directed CAR T-cell therapy in patients with relapsed/refractory (R/R) multiple myeloma. The updated results from KarMMa trial continue to demonstrate deep, durable responses with ide-cel in heavily pretreated patients with R/R multiple myeloma. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

More from Larry Anderson

0:52
Inequality in access to CAR-T therapy in multiple myeloma and the importance of addressing this
Larry Anderson • 28 Sep 2023
2:58
The impact of bridging therapy on the outcomes of patients with R/R myeloma treated with ide-cel
Larry Anderson • 28 Sep 2023
0:59
Further improvements of ide-cel therapy in KarMMa trials
Larry Anderson • 4 Jun 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals